Johnson & Johnson Reports Q2 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St climbs as cooling inflation tempers Fed rate-hike concerns
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
'Sunshine and Blue Skies' Ahead For Johnson & Johnson (JNJ) Following Strong Q2 Beat
July 21, 2021 9:53 AM EDTEarlier today, Johnson & Johnson (NYSE: JNJ) reported a strong Q2 beat both on the top and bottom lines: EPS of $2.48, $0.22 better than the analyst estimates of $2.26, and revenues of $23.31B versus the consensus estimate of $22.19B.
The company also revised its full-year guidance to the upside: FY2021 EPS of $9.60-$9.70, vs consensus of... More
Johnson & Johnson (JNJ) Tops Q2 EPS by 22c, Updates FY Guidance
July 21, 2021 6:28 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.48, $0.22 better than the analyst estimate of $2.26. Revenue for the quarter came in at $23.31 billion versus the consensus estimate of $22.19 billion.
GUIDANCE:
Johnson & Johnson sees FY2021 EPS of $9.60-$9.70, versus the consensus of $9.52.... More
